Aquestive Therapeutics’ (AQST) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST – Free Report) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock. Several other analysts have also recently commented on AQST. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a report on […]